

BC AFC Sotalol Initiation and Titration Pathway (For Prescribers)

Document Purpose: Standardized recommendations for initiation of **Sotalol** and ongoing monitoring/patient management

Clinical Indication:

• Symptomatic AF in the absence of structural heart disease or decompensated heart failure

Absolute Contraindications:

- Pre-existing QTc prolongation (congenital or acquired long QT syndromes)
 - Consider avoiding sotalol in the presence of a QTc >440 msec (men) or >460 msec (women) in the absence of a pre-existing bundle branch block
- Sinus bradycardia (<50 bpm) or sick sinus syndrome (unless functioning pacemaker is present)
- High degree atrioventricular conduction disorders (unless functioning pacemaker is present)
- Severe renal impairment (CrCl < 40 ml/min)

Relative Contraindications (caution for use):

- Advanced age (>75 years of age)
- Reactive airway disease
- Systolic heart failure (use cautiously if LVEF <40%)
- Significant left ventricular hypertrophy
 - \circ $\;$ LVH with repolarization abnormalities (ST and T wave changes) on ECG $\;$
 - LVH >1.4 cm on echocardiogram
- Hypokalemia or hypomagnesemia (correct imbalances prior to use and throughout therapy)
- Should be avoided in patients at high risk of Torsades de Pointes VT
 - i.e. women aged >65 y taking diuretics or those with renal insufficiency

Baseline Investigations:


- Blood pressure
- ECG (within 1 week)
- Echocardiogram (or other assessment of LV function; within 1 year)
- Laboratory investigations (within 1 month) Serum electrolytes, and Serum Creatinine/eGFR

Dosing:

- Starting Dose
 - 40 mg BID (optional) or 80 mg BID (usual starting dose)
- Renal Dosing
 - o CrCl 40-60 ml/min: adjust dose to once daily
 - CrCl < 40 ml/min: contraindicated
- Titration: See table below

Current Dose	Increase Dose to	Decrease Dose to
40 mg BID	80 mg BID	
80 mg BID	120 mg BID	40 mg BID
120 mg BID	160 mg BID	80 mg BID
160 mg BID		120 mg BID

If the patient's dosing does not fall into one of the intervals, contact the EP/cardiologist or consult clinical pharmacist for closest equivalent dosing.



Monitoring:

Parameter	Frequency	Considerations
ECG	Within 7 days of a dose change Every 6-12 months if stable	 Notify prescriber if any of the following develop: >25% increase from baseline QTc (>500ms) Heart rate <50 bpm If prescriber not immediately available then consider reducing dose or temporary discontinuation
Patient response	With each dose change and at each patient follow-up appointment	 If symptoms improved and/or decreased frequency of episodes: Maintain at current dose and arrange follow-up (including holter) as per algorithm. If no/minimal improvement in AF symptoms and patient tolerating sotalol at current dose

		 Titrate sotalol per protocol and send patient
		for a repeat ECG within 7 days
Medication	With each dose change,	Exacerbation/New onset of HF symptoms
Tolerance	and at each patient	 Strongly consider holding sotalol pending the
	follow-up appointment	outcome of clinical review
		Exacerbation of reactive airway disease
		 Consider holding pending the outcome of
		clinical review
		Syncope
		 Discontinue sotalol, report to ER
		Dizziness/lightheadedness
		 If acute onset, severe, or persistently
		problematic send for clinical review
		 Consider holding pending clinical review
		Headache, sleep disturbance, depression, GI upset
		 Supportive measures (up to 1 month)
		 Notify prescriber if symptoms persists and are
		problematic
24 hour Holter	Once patient maintained	Arrange for Holter and follow-up visit (in-clinic or
Monitor	on stable dose	telehealth) in 3-6 months following last dose
WOILDI		
	From Concerthe	adjustment (or as previously scheduled)
Electrolytes & Serum	Every 6 months	• If \downarrow K ⁺ or \downarrow Mg ²⁺
Creatinine	(Q3months if on	 Supplement and repeat labs in 1 week
	diuretics, nephrotoxic	(preferably delegate to GP)
	meds or baseline renal	CrCl 40-60 ml/min: adjust dose to once daily
	insufficiency)	CrCl < 40 ml/min: contraindicated

Patient counseling to include:

- Discuss any new mediation starts (OTC, prescription) with community pharmacist or prescriber
 - o These include antibiotics, antihistamines, antidepressants, diuretics
- Use care to avoid dehydration as this may provoke electrolyte disturbances or renal dysfunction
 - Consider consulting primary care provider if severe diarrhea/vomiting/dehydration
- Stop sotalol and report to ER if any syncopal episodes

Tapering / Discontinuation Schedule

- Consider tapering gradually to discontinue, particularly in patients with CAD.
 - Abrupt withdrawal has been associated with acute tachycardia, hypertension, and/or ischemia.
 - If sotalol must be discontinued abruptly, consider the use of an interim alternate beta-blocker if worsening angina or acute coronary insufficiency.
- Suggested tapering schedule:

Current Dose	Decrease Dose to	Duration
40 mg BID	20mg BID (optional)	3 - 5 days then discontinue
80 mg BID	40 mg BID	3 - 5 days then next decrease
120 mg BID	80 mg BID	3 - 5 days then next decrease
160 mg BID	120 mg BID	3 - 5 days then next decrease

Wash-out period prior to initiating alternate antiarrhythmic

• 3 days